- Record: found
- Abstract: found
- Article: not found
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.
Tamara Isakova
1 ,
Huiliang Xie ,
Wei Yang ,
Dawei Xie ,
Amanda Hyre Anderson ,
Julia Scialla ,
Patricia Wahl ,
Orlando M Gutiérrez ,
Susan Steigerwalt ,
Jiang He ,
Stanley Schwartz ,
Joan Lo ,
Akinlolu Ojo ,
James Sondheimer ,
Chi-yuan Hsu ,
James Lash ,
Mary Leonard ,
John W Kusek ,
Harold I Feldman ,
Myles Wolf
Jun 15 2011
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
A high level of the phosphate-regulating hormone fibroblast growth factor 23 (FGF-23) is associated with mortality in patients with end-stage renal disease, but little is known about its relationship with adverse outcomes in the much larger population of patients with earlier stages of chronic kidney disease.